Tenderwize
Wróć do wyszukiwania

Open-house biologics rebate agreement for Natalizumab (subcutaneous formulation)

Techniker Krankenkasse·Hamburg, Germany·Deadline Jan 30, 2028 · 523 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-36 - Natalizumab (Darreichungsform zur subkutanen Injektion)

62/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

62 / 100

Złożoność

58 / 100

Czynniki ryzyka

Contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature or by...

Participation is limited to pharmaceutical undertakings for the relevant medicinal product and requires valid authorisa...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Conclusion of pharmaceutical rebate agreements for Natalizumab (subcutaneous injection formulation).
  • Open-house arrangement with uniform contractual conditions and no individual negotiations.
Pokaż pełne podsumowanie

Open-house pharmaceutical supply arrangement for Natalizumab (subcutaneous formulation) in Germany, led by Techniker Krankenkasse with HEK and hkk as participating buyers. The notice states that any suitable pharmaceutical undertaking may join during the contract period, with no exclusivity and no individual negotiations. The contract runs for up to 24 months from 01.02.2026 and ends no later than 31.01.2028. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the documents are only available electronically. No contract value is stated.

Ryzyka

Contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature or by...

Participation is limited to pharmaceutical undertakings for the relevant medicinal product and requires valid authorisa...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal product(s).
  • Applicant must have its seat in Germany, another EU Member State, or another EEA State.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product(s), or otherwise be entitled to place them on the market in its own name.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open-house biologics rebate agreement for Natalizumab (subcutaneous formulation)

Single lot covering the conclusion of pharmaceutical rebate agreements under Section 130a(8) SGB V for Natalizumab in subcutaneous formulation. Scope is nationwide in Germany. The notice says the arrangement is open-house, with uniform terms, no exclusivity, and no individual negotiations. Lot information is taken from structured data and the notice text.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Jan 2026 - Jan 2028

Kategoria

Pharmaceutical products

Termin

Deadline Jan 30, 2028

Szczegóły zamówienia

Data publikacji
23 Nov 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
776899-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3